166 related articles for article (PubMed ID: 29709487)
1. Urea Improves Stability of Inactivated Polio Vaccine Serotype 3 During Lyophilization and Storage in Dried Formulations.
Qi W; Orgel S; Francon A; Randolph TW; Carpenter JF
J Pharm Sci; 2018 Aug; 107(8):2070-2078. PubMed ID: 29709487
[TBL] [Abstract][Full Text] [Related]
2. Development of Thermostable Lyophilized Sabin Inactivated Poliovirus Vaccine.
Shin WJ; Hara D; Gbormittah F; Chang H; Chang BS; Jung JU
mBio; 2018 Nov; 9(6):. PubMed ID: 30482835
[TBL] [Abstract][Full Text] [Related]
3. Development of thermostable lyophilized inactivated polio vaccine.
Kraan H; van Herpen P; Kersten G; Amorij JP
Pharm Res; 2014 Oct; 31(10):2618-29. PubMed ID: 24760448
[TBL] [Abstract][Full Text] [Related]
4. Development of Stabilizing Formulations of a Trivalent Inactivated Poliovirus Vaccine in a Dried State for Delivery in the Nanopatch™ Microprojection Array.
Wan Y; Hickey JM; Bird C; Witham K; Fahey P; Forster A; Joshi SB; Volkin DB
J Pharm Sci; 2018 Jun; 107(6):1540-1551. PubMed ID: 29421219
[TBL] [Abstract][Full Text] [Related]
5. Rational design of heat stable lyophilized rotavirus vaccine formulations.
Madan M; Sikriwal D; Sharma G; Shukla N; Mandyal AK; Kale S; Gill D
Hum Vaccin Immunother; 2018; 14(9):2132-2141. PubMed ID: 29953317
[TBL] [Abstract][Full Text] [Related]
6. Incompatibility of lyophilized inactivated polio vaccine with liquid pentavalent whole-cell-pertussis-containing vaccine.
Kraan H; Ten Have R; van der Maas L; Kersten G; Amorij JP
Vaccine; 2016 Aug; 34(38):4572-4578. PubMed ID: 27470209
[TBL] [Abstract][Full Text] [Related]
7. Thin silk fibroin films as a dried format for temperature stabilization of inactivated polio vaccine.
Stinson JA; Palmer CR; Miller DP; Li AB; Lightner K; Jost H; Weldon WC; Oberste MS; Kluge JA; Kosuda KM
Vaccine; 2020 Feb; 38(7):1652-1660. PubMed ID: 31959422
[TBL] [Abstract][Full Text] [Related]
8. The effect of formulation on spray dried Sabin inactivated polio vaccine.
Kanojia G; Ten Have R; Brugmans D; Soema PC; Frijlink HW; Amorij JP; Kersten G
Eur J Pharm Biopharm; 2018 Aug; 129():21-29. PubMed ID: 29787800
[TBL] [Abstract][Full Text] [Related]
9. Development of a thermostable microneedle patch for polio vaccination.
Kolluru C; Gomaa Y; Prausnitz MR
Drug Deliv Transl Res; 2019 Feb; 9(1):192-203. PubMed ID: 30542944
[TBL] [Abstract][Full Text] [Related]
10. Cold-Chain Adaptability During Introduction of Inactivated Polio Vaccine in Bangladesh, 2015.
Billah MM; Zaman K; Estivariz CF; Snider CJ; Anand A; Hampton LM; Bari TIA; Russell KL; Chai SJ
J Infect Dis; 2017 Jul; 216(suppl_1):S114-S121. PubMed ID: 28838173
[TBL] [Abstract][Full Text] [Related]
11. Role of phenol red in the stabilization of the Sabin type 2 inactivated polio vaccine at various pH values.
Huijuan Y; Xiaohu D; Ze L; Wei C; Jian Z; Lei M; Shaohui S; Weidong L; Guoyang L
J Med Virol; 2019 Jan; 91(1):22-30. PubMed ID: 30133803
[TBL] [Abstract][Full Text] [Related]
12. Measurement of the kinetics of protein unfolding in viscous systems and implications for protein stability in freeze-drying.
Tang XC; Pikal MJ
Pharm Res; 2005 Jul; 22(7):1176-85. PubMed ID: 16028019
[TBL] [Abstract][Full Text] [Related]
13. Long-term evaluation of mucosal and systemic immunity and protection conferred by different polio booster vaccines.
Xiao Y; Daniell H
Vaccine; 2017 Sep; 35(40):5418-5425. PubMed ID: 28111147
[TBL] [Abstract][Full Text] [Related]
14. Formulation approach for the development of a stable, lyophilized formaldehyde-containing vaccine.
Clausi A; Chouvenc P
Eur J Pharm Biopharm; 2013 Oct; 85(2):272-8. PubMed ID: 23673385
[TBL] [Abstract][Full Text] [Related]
15. Alternative delivery of a thermostable inactivated polio vaccine.
Kraan H; Ploemen I; van de Wijdeven G; Que I; Löwik C; Kersten G; Amorij JP
Vaccine; 2015 Apr; 33(17):2030-7. PubMed ID: 25772676
[TBL] [Abstract][Full Text] [Related]
16. Freeze-Drying of L-Arginine/Sucrose-Based Protein Formulations, Part 2: Optimization of Formulation Design and Freeze-Drying Process Conditions for an L-Arginine Chloride-Based Protein Formulation System.
Stärtzel P; Gieseler H; Gieseler M; Abdul-Fattah AM; Adler M; Mahler HC; Goldbach P
J Pharm Sci; 2015 Dec; 104(12):4241-4256. PubMed ID: 26422647
[TBL] [Abstract][Full Text] [Related]
17. The effect of stabilizers and denaturants on the cold denaturation temperatures of proteins and implications for freeze-drying.
Tang XC; Pikal MJ
Pharm Res; 2005 Jul; 22(7):1167-75. PubMed ID: 16028018
[TBL] [Abstract][Full Text] [Related]
18. Stability of collapse lyophilized influenza vaccine formulations.
Anamur C; Winter G; Engert J
Int J Pharm; 2015 Apr; 483(1-2):131-41. PubMed ID: 25660049
[TBL] [Abstract][Full Text] [Related]
19. Preformulation study of highly purified inactivated polio vaccine, serotype 3.
Qi W; Zeng Y; Orgel S; Francon A; Kim JH; Randolph TW; Carpenter JF; Middaugh CR
J Pharm Sci; 2014 Jan; 103(1):140-51. PubMed ID: 24282078
[TBL] [Abstract][Full Text] [Related]
20. Effect of pH on stability of recombinant botulinum serotype A vaccine in aqueous solution and during storage of freeze-dried formulations.
Roy S; Henderson I; Nayar R; Randolph TW; Carpenter JF
J Pharm Sci; 2008 Dec; 97(12):5132-46. PubMed ID: 18399536
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
